First commercial kit to quantify protein modification in single cells 03.11.20222’First commercial kit to quantify protein modification in single cells launched by Singleron BiotechnologiesCologne, Germany, November 03, 2022Singleron Biotechnologies, a pioneer in development and commercialization of innovative single cell sequencing analysis solutions, announces the launch of the first commercially available product that can quantify protein glycosylation at single cell level, ProMoSCOPE™ kit. This product uses a unique single-cell multi-omics technology that enables simultaneous quantification of glycosylation levels and gene expression on the single-cell level, making advanced high-throughput single-cell multimodal analysis more accessible.Previously available single-cell sequencing technologies mainly focused on single-cell gene expression profiles, while proteins are studied to a lesser extent at a single-cell resolution. As post-translational modification of proteins, such as glycosylation, plays important roles in cellular function and diseases, ProMoSCOPE kit enables researchers to gain further insights to advance their understanding of complex biological systems.ProMoSCOPE™ makes it possible to obtain quantitative multimodal information on both glycosylation and gene expression from the same single cells. Along with the rest of Singleron’s single cell multi-omic portfolio, this new product adds to the toolbox to advance translational research. ProMoSCOPE expands Singleron’s unique multi-omics solutions that include FocuSCOPE®, a high-throughput single-cell sequencing solution that can detect both genetic variants and transcriptome from the same single cells, and DynaSCOPE®, a single cell sequencing kit enabling to study RNA dynamics on a single cell level.About SingleronFounded in 2018, Singleron develops and commercializes single-cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic devices, reagents, software analysis and database solutions that facilitate high-throughput single-cell analysis. The company currently has offices, laboratories, and manufacturing facilities in Germany, Singapore, China, and the US. Its products are used in over 2000 laboratories in hospitals, research institutes, and pharmaceutical companies.Media Contact Email: info@singleronbio.comCheck out our latest news and events Learn more 24.10.28 B2B-RARE: Bench to Bedside – Rapid Diagnosis and Personalized Treatment of Rare Neuromuscular Diseases For the German version of the article, see here. NRW, 28th October 2024 – More than 400 genetically determined neuromuscular diseases (NME) are rare diseases…. Read more 24.09.11 Singleron Launches New All-in-One sCelLiVE® Tissue Dissociation Kit for Skin Cologne, 11th September 2024 – Singleron announced the launch of sCelLiVE® Tissue Dissociation Kit (Skin) (sCelLiVE Skin), a new all-in-one solution for human and mouse skin tissue…. Read more 24.04.11 Bioinformatics Bootcamp Singleron Biotechnologies regularly offers 8-week bioinformatics beginner courses to support single cell sequencing users. No bioinformatics background required. Limited seats available.Contact us at info@singleron.bio to receive further… Read more
24.10.28 B2B-RARE: Bench to Bedside – Rapid Diagnosis and Personalized Treatment of Rare Neuromuscular Diseases For the German version of the article, see here. NRW, 28th October 2024 – More than 400 genetically determined neuromuscular diseases (NME) are rare diseases…. Read more
24.09.11 Singleron Launches New All-in-One sCelLiVE® Tissue Dissociation Kit for Skin Cologne, 11th September 2024 – Singleron announced the launch of sCelLiVE® Tissue Dissociation Kit (Skin) (sCelLiVE Skin), a new all-in-one solution for human and mouse skin tissue…. Read more
24.04.11 Bioinformatics Bootcamp Singleron Biotechnologies regularly offers 8-week bioinformatics beginner courses to support single cell sequencing users. No bioinformatics background required. Limited seats available.Contact us at info@singleron.bio to receive further… Read more